Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

5 treatments under study, led by Estazolam

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 2 (2)

Trial Status

Completed2
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06278077Phase 2Completed

Neurexan - a Clinical Trial in Short-Term Insomnia Patients

NCT06212934Not ApplicableUnknownPrimary

"Chou's Tiaoshen" Acupoints for Short-term Insomnia.

NCT02671760Phase 2CompletedPrimary

Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia

Showing all 3 trials

Research Network

Common Treatments

  • Estazolam1
  • Acupuncture1
  • Sm11
  • Comparator1
  • Neurexan1

Active Sponsors

  • Beijing Hospital of Traditional Chinese Medicine1
  • Clinilabs, Inc.1
  • Biologische Heilmittel Heel GmbH1
  • Sequential Medicine Ltd1

Top Investigators

Related Conditions

  • Insomnia1
  • Stress Reaction1

Activity Timeline